Novartis: to present new data at ECTRIMS

(CercleFinance.com) - Novartis is due to present a wide range of portfolio data at ECTRIMS for people with multiple sclerosis.


Novartis will present 41 data at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be held from Wednesday 13 to Friday 15 October 2021.

These data reinforce Kesimpta's role as the first choice treatment for relapsing forms of MS, highlighting its long-term safety and efficacy for patients and physicians, Novartis said.

The group will also initiate pivotal Phase III trials to study remibrutinib in MS patients. It said that Remibrutinib (LOU064) is a potentially best-in-class, highly selective and potent covalent BTK inhibitor with favourable safety data based on clinical experience to date.


Copyright (c) 2021 CercleFinance.com. All rights reserved.